Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
5.71
+0.15 (2.70%)
At close: Dec 18, 2025, 4:00 PM EST
5.66
-0.05 (-0.88%)
After-hours: Dec 18, 2025, 7:26 PM EST
Immix Biopharma Employees
As of December 31, 2024, Immix Biopharma had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-$1,122,040
Market Cap
191.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21 | 4 | 23.53% |
| Dec 31, 2023 | 17 | 6 | 54.55% |
| Dec 31, 2022 | 11 | 9 | 450.00% |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMMX News
- 8 days ago - Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition - Seeking Alpha
- 9 days ago - Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 11 days ago - Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 11 days ago - At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - GlobeNewsWire
- 5 weeks ago - Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch - GlobeNewsWire
- 6 weeks ago - Immix Biopharma: I Am Surprised To Reaffirm A 'Buy' - Seeking Alpha
- 6 weeks ago - Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 - GlobeNewsWire
- 2 months ago - Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire